Savior Lifetec

Savior Lifetec FCF Margin

The Free Cash Flow Margin of Savior Lifetec (4167.TWO) as of Oct 25, 2026 is -13.67 %. In the previous year, Free Cash Flow Margin was 32.85 % — a change of -141.61% (lower).

FCF Margin

-13.67 %

YoY

-141.61%

Last updated:

Free Cash Flow Margin of Savior Lifetec is 2025 -13.67 % . Free Cash Flow Margin of Savior Lifetec was 2024 32.85 % . It decreases by -141.61% lower compared to the previous year.

The Savior Lifetec FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2018
-35.71 TWD
Jan 1, 2019
-3.25 TWD
Jan 1, 2020
-6.86 TWD
Jan 1, 2021
-15.14 TWD
Jan 1, 2022
43.26 TWD
Jan 1, 2023
35.24 TWD
Jan 1, 2024
32.85 TWD
Jan 1, 2025
-13.67 TWD
The Savior Lifetec FCF Margin history
YEARFCF MarginYoY
-13.67 %-141.61%
32.85 %-6.76%
35.24 %-18.55%
43.26 %-385.82%
-15.14 %+120.79%
-6.86 %+110.91%
-3.25 %-90.90%
-35.71 %-547.92%
7.97 %-179.25%
-10.06 %-83.78%
-62.03 %+29.71%
-47.82 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Savior Lifetec Stock analysis

What does Savior Lifetec do? Savior Lifetec Corp develops, produces, and sells active pharmaceutical ingredients and finished dosage formulations, including Meropenem, Imipenem/Cilastatin, and Ertapenem, which are used as broad-spectrum antibiotics. The company provides APIs intermediates and bio-pharmaceutical technology services, distributing its products to Europe, the Americas, Asia, and other global markets. Its primary revenue streams come from the sale of pharmaceutical products and technology services to international markets. The company's product portfolio focuses on antibiotics such as Meropenem and Ertapenem, which are sold as finished dosage formulations. APIs intermediates are supplied to clients in the pharmaceutical industry, while bio-pharmaceutical technology services support clients in drug development and manufacturing. These offerings target global pharmaceutical companies seeking reliable supply chains and technical expertise. Savior Lifetec Corp's customers include pharmaceutical firms in Europe, the Americas, Asia, and other regions that require active pharmaceutical ingredients and specialized technology services. The company generates revenue through direct sales of its antibiotic formulations and API intermediates, as well as through contractual agreements for bio-pharmaceutical technology services. Savior Lifetec is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Savior Lifetec stock

Free Cash Flow Margin of Savior Lifetec is -13.67 % in 2025.

Free Cash Flow Margin of Savior Lifetec changed from 32.85 % to -13.67 %, representing a -141.61% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Savior Lifetec since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Savior Lifetec with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Savior Lifetec

All Key Metrics — Savior Lifetec